Pfizer's RSV acquisition target is Novo Ventures portfolio company

Reviral, which Pfizer intends to acquire in a deal that could total USD 525m, has received several investments from Novo Ventures.
Photo: Novo Holdings / PR
Photo: Novo Holdings / PR

Pfizer has entered into an acquisition agreement with London based Reviral, which develops antiviral treatments for respiratory syncytial virus (RSV), in a deal that could reach USD 525m.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading